BioSpace News Archive

twoXAR Pharmaceuticals, a drug discovery and development company focused on bringing first-in-class small molecules to market, today announced that two novel leads for the potential treatment of chronic kidney disease (CKD), TXR-1208 and TXR-1210, demonstrated significant efficacy and excellent tolerability in preclinical studies.

Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that under the Company’s Employee Share Purchase Plan (“the ESPP”),

The American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine have recommended that COVID-19 vaccines “not be withheld” from pregnant or lactating patients if they are at high risk of complications from COVID.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

In late 2020, VH Bio and Celemics formalised a new partnership after the innovative NGS target enrichment kit manufacturer chose VH Bio as their exclusive distribution partner for the UK and Republic of Ireland.

FARE, the world’s leading non-governmental organization engaged in food allergy advocacy and the largest private funder of food allergy research, announced that the Food Allergy Safety, Treatment, Education and Research Act, S. 578, was unanimously passed last night by the United States Senate.

SynerFuse™, a developer of a novel implantable neurostimulator intended to treat chronic low-back pain without the use of addictive opioids, announced a strategic development and manufacturing relationship with Cirtec Medical Corporation to support their current investigational and future commercial technology needs.

The researchers can comment on a wide range of topics from a science-based perspective and are available for media interviews

Interim review by independent data monitoring committee (DMC) found no meaningful reduction in the overall mortality rate in Phase 1/2 study

Best-in-class, guided risk analysis and structured data management enable medical device companies to develop safe, regulatory-compliant products